Reversing Therapy Resistance With Epigenetic-Immune Modification
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Tamoxifen|DRUG: Vorinostat|DRUG: Pembrolizumab
Sponsor: University of California, San Francisco
Collaborators: Avon Foundation|Merck Sharp & Dohme LLC